175696-71-6

Basic information

• Product Name: (3-PIPERIDINOPHENYL)METHYLAMINE
• Synonyms: (3-PIPERIDINOPHENYL)METHYLAMINE;3-PIPERIDINOBENZYLAMINE;1-(3-PIPERIDIN-1YLPHENYL)METHANAMINE;1-(3-Piperidin-1ylphenyl)methanamine 95%;(3-Piperidin-1-ylphenyl)methylamine;3-(Piperidin-1-yl)benzylamine;3-(Piperidin-1-yl)benzylamine 95%;3-(1-Piperidyl)benzylaMine
• CAS NO: 175696-71-6
• Molecular Formula: C₁₂H₁₈N₂
• Molecular Weight: 190.28
• Mol File: 175696-71-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 343.8 °C at 760 mmHg
• Flash Point: 142.3 °C
• Appearance: /
• Density: 1.047 g/cm³
• Vapor Pressure: 6.88E-05mmHg at 25°C
• Refractive Index: 1.568
• PKA: 9.39±0.10(Predicted)
• CAS DataBase Reference: (3-PIPERIDINOPHENYL)METHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (3-PIPERIDINOPHENYL)METHYLAMINE(175696-71-6)
• EPA Substance Registry System: (3-PIPERIDINOPHENYL)METHYLAMINE(175696-71-6)

Safety Data

• Hazard Codes: C,Xi
• Statements: 41
• Safety Statements: 26-39
• HazardClass: IRRITANT
• Hazardous Substances Data: 175696-71-6(Hazardous Substances Data)

Usage

General Description

"(3-Piperidinophenyl)methylamine" is a chemical compound with the molecular formula C11H16N2. It is a derivative of phenethylamine and a psychostimulant. The compound has been studied for its potential use in the treatment of depression and other psychiatric disorders. It has also been investigated for its potential as a drug for the treatment of Parkinson's disease. In addition, it has been used in research as a ligand for various receptors and has demonstrated a range of biological activities. However, due to its psychoactive and potentially addictive nature, it is not approved for medical use and is considered a controlled substance.

InChI:InChI=1/C12H18N2/c13-10-11-5-4-6-12(9-11)14-7-2-1-3-8-14/h4-6,9H,1-3,7-8,10,13H2

Upstream product

• 403-54-3 m-Fluorobenzonitrile 
• 110-89-4 piperidine 
• 2237-30-1 m-cyanoaniline 
• 175696-74-9 3-(piperidin-1-yl)benzonitrile 
• 111-24-0 1,5-dibromo-pentane 

Relevant articles and documents

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters

With the ever-increasing instances of resistance to frontline TB drugs there is the need to develop novel strategies to fight the worldwide TB epidemic. Boosting the effect of the existing second-line antibiotic ethionamide by inhibiting the mycobacterial

Pyrimidine derivatives useful as inhibitors of PKC-theta

Disclosed are novel compounds of formula (I): wherein X, Y, R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.